











Supplemental Figure 1 | Sequential image-based clustering solutions resolve different degrees of heterogeneity across WSIs. Clustering of a diffuse glioma WSI with partition solutions ranging from k=2-7 (i-vi). In most cases, early HAVOC partitions separate large histomorphologic differences such as tumoral vs normal brain tissue (green versus red, k=2). Additional partitions allow for the identification of more subtle histomorphological differences, such as glioma regions with and without edema (cyan vs blue, k=7, respectively).



Supplemental Figure 2 | HAVOC resolution of intra-tumoral niches in diffuse glioma. (a) Representative image patches from the discrete histomorphologic HAVOC partitions for the slide shown in Fig 1. Regions align with pathologist-defined glioma niches including cellular tumor, infiltrating tumor, white and gray matter. More subtle areas with tumoral edema are also detected. (b) Cartoon highlighting how spatial distribution differences of tumor patterns across entire slide were analyzed. (c) vertical cumulative distribution plot of the overall fraction of tiles from each HAVOC-defined cluster in Fig 1d across entire WSI highlighting non-random spatial distributions of defined histomorphologies (Kolmogorov–Smirnov statistic of distribution of cellular tumor<sub>cyan</sub> vs infiltrating tumor<sub>purple</sub> = 0.375, p=0.0068).



Supplemental Figure 3 | Highest DLFV *r* between HAVOC-defined partitions across six representative WSI increasing from k=2 to k=8. In the majority of encountered specimen, irrespective of the initial partition correlation, the degree of pathologist discernible histomorphologic heterogeneity (DLFV  $r \sim 0.84$ ) reaches saturation after ~6-7 WSI partitions.



**Supplemental Figure 4** | **Molecular expression patterns and DLFVs covary across diffuse glioma niches.** Comparison of region-to-region (a) proteomic and (b) transcriptomic versus DLFV Pearson correlations (*r*) between well-defined glioma niches (leading edge (LE), infiltrating tumor (IT), and cellular tumor (CT)). Both modalities show a strong correlation. Proteomic data retrieved from Lam et al (Nature *Communications*, 2022) and transcriptomic data taken from the Ivy Gap database (Puchalski et al, *Science*, 2018).



Deep Learning-based Color Tiled Map





LC-MS/MS Analysis

Original Whole Slide Image

**Supplemental Figure 5** | **Schematic of HAVOC profiling workflow.** H&E-stained WSI are assessed by HAVOC to define spatial distribution of intra-tumoral histomorphological differences. HAVOC-defined regions are subsequently isolated with laser-capture microdissection and prepared for LC-MS/MS proteomic profiling.

a Patient I



Cell density: Yellow (0.53) / Green (0.67)





**b** Patient IV



Cell density: Yellow (0.92) / Red (0.79)



Cell density: Blue (1.08) / Red (0.91)

iii)



**Regional Protein Signatures** 



**Regional Protein Signatures** VI\_RED-2 VI\_RED-1 VI\_RED-3 VI\_GREEN-3 VI\_GREEN-1 VI\_GREEN-2 VI\_RED-2 VI\_RED-1 VI\_RED-3 VI\_GREEN-GREEN-GREEN-L IN. Pearson correlation 0 0.5 1

C Patient VI



# **Supplemental Figure 6 | Mapping of spatial protein-based pathway differences in high grade glioma using HAVOC.** Additional examples of spatial differences in individual cases of diffuse gliomas guided by HAVOC.



#### HAVOC Definition of Tumor Proliferative Programs



Supplemental Figure 7 | Histomic heterogeneity HAVOC distances (r) correlate with proliferation differences. Relationship between estimated proliferation indices (Ki-67) and regional DLFV-generated r values across HAVOC partitions. n=4, \*\*\* denotes p<0.0001.

**Supplemental Figure 8** | **Regional variation of deep learning features in a glioblastoma.** Volcano plot highlighting differential DLF activation between the HAVOC-defined partitions. The H&E and HAVOC map from Figure 2 are included here as a reference.





Supplemental Figure 9 | Representative H&E images patches from different clustered regions from Figure 3.

**Supplemental Figure 10** | **t-SNE plot of all 10,973 0.27 mm<sup>2</sup> image patches from the entire tumor in Figure 3.** Coloured tiles correspond to tumor cluster colour IDs indicated in Figure 3c. From right to left, there is a gradient transitioning from hyper-cellular nodules (blue), cellular tumor (orange), purple (moderate 1), green (moderate 2) and non-tumor/low tumor cellularity (red). Gray points highlight non-cellular cluster (hemorrhage/edge tiles).

#### Patient Va











b

а





**Regional Protein Signatures** 



**Supplemental Figure 11 | HAVOC mapping across independent slides align with overall molecular correlations (a)** Another example of a slide pair analyzed concurrently by HAVOC and molecular analysis. **(b)** Integrated DLFV correlation matrices across both slides define a distinct infiltrative compartment and a more cellular tumor region on initial slide. The accompanying slide shows 2 proposed tumor patterns encircling a central necrotic region. These multi-slide maps are in agreement with global patterns of proteomic variations derived from each of the major HAVOC defined partitions.

## Patient II

Group	Region (avg	. cell density)	Block IIa	Block IIb		
Croup	lla	llb	Alline			
Ultra-high	_	BLUE (1.31)		<b>*</b>		
High	GREEN (0.83)	RED (0.94)		<b>1</b> ,		
	YELLOW		WYY S. Ja			
Mid	(0.67)	-				
		YELLOW		Carlos a surface		
Low	-	(0.44)				

# Patient III

#### Block IIIa

Block IIIb

Group	Region (avg. ce	-	
Group	Illa	IIIb	with the second
Ultra-high	-	-	1 2 -
High	-	-	1 25
Mid	YELLOW (0.60)	GREEN (0.72)	9
Low	GREEN (0.46)	RED (0.51)	





# Patient V

Block Va

Block Vb

Creation	Region (avg. cell density)					
Group	Va	Vb				
Ultra-high	-					
	YELLOW (0.85)	BLUE (1.09)				
High	RED (0.79)	RED (0.91)				
Mid	-	-				
Low	-	-				





**Supplemental Figure 12** | **Regional cell density estimates align with HAVOC mapping across independent slides.** Correlation of cell densities of closely clustered regions further supports the non-random partitioning and grouping of regions by HAVOC.

#### 64-signature gene expression analysis



**Supplemental Figure 13** | **Hierarchical clustering of proteomics signatures.** Enrichment of 64 pre-selected genesets that were previously deemed informative in GBM (Lam et al, 2022) was calculated by ssGSEA and followed by hierarchical clustering. This unsupervised approach results in samples being mainly grouped by tissue, and with limited intra-sample regional separation.

Single cell RNAseq (Richards et al)



**Supplemental Figure 14** | **Varying distributions along the Astro-ES axis at the single-cell level in glioma stem cells (n=28) and patient-derived GBM cells (n=6);** dataset previously published by Richards et al.

#### a Single-cell RNA Seq Projection











Supplemental Figure 15 | HAVOC partitioning defines metastatic subclones and peritumoral changes in an experimental lung cancer model. (a) Spatial RNAseq image taken from Zhao et al. as a reference for ground truth. In addition to lesion segmentation, this approach highlight peritumoral immune infiltrates within the neighbouring liver tissue parenchyma. (b-c). HAVOC analysis at both a tile width of 1024 (panel b) and 512 (panel c) pixels defined five relatively homogeneous tumoral populations. These sub-partitions were relatively stable across the different tile sizes, but smaller tiles sizes provide higher resolution in specific cases in which pattern was predominantly driven by nuclear patterns. (d). Using the silhouette method, the five tumors in panel c. group into two major clusters (highlighted in red).











v)







Supplemental Figure 16 | Sequential image-based clustering solutions resolve different degrees of heterogeneity across WSIs. Clustering of image patches of a WSI of a lung adenosquamous carcinoma with partition solutions ranging from k=2-9. The major squamoid pattern of morphologic heterogeneity was resolved at k=4 (blue vs green, r = 0.86). Subsequent partitions of the adenosquamous regions showed more minor histomic differences that were not appreciated by human experts as significant (Blue vs Cyan, r = 0.95).

# Supplemental Table 1

profiling	Diagnosis	Glioblastoma, WHO Grade 4	High grade glioma (WHO grade 3)	Glioblastoma, WHO Grade 4	Glioblastoma, WHO Grade 4	Glioblastoma, WHO Grade 4	Glioblastoma, WHO Grade 4
<b>C-based regional</b>	MGMT Promoter Methylation (Sequencing)	MGMT Promoter Methylation (Sequencing) Positive		Negative	Negative	Positive	N/A
or HAVO	p53 (IHC)	WT	WT	Mutant	WT	WT	ΤW
ohort used f	IDH ATRX Method (IHC) IHC Retained		Retained	Retained	Retained	Retained	Retained
rade glioma co			Sequencing	IHC	IHC	IHC	IHC
of high-g	IDH Status	ΤW	WT	МТ	WT	ΤW	ΤW
cal and pathological details of	Location	Right temporal	Right temporal	Right parietal/ frontal	Right parietal/ frontal	Right frontal	Left parietal/ occipital
	Sex	Female	Male	Male	Male	Female	Male
	Age Range	66-70	46-50	56-60	51-55	56-60	56-60
Table 1  Clin	Primary vs Secondary	Primary	Primary	Primary	Primary	Primary	Primary
plementary	Patient ID (Block)	I (Block 1B)	IIa (Block 3C) IIb (Block 3D)	IIIa (Block 1A) IIIb (Block 1B)	IV (Block 2F)	Va (Block 2A) Vb (Block 2D)	VI (Block 2C)

IdnS

# Supplemental Table 2

	able
. For	avail
/ <b>O</b> C	not
HAV	lotes
l by	A dei
lyzed	I. N//
anal	uced
ases	ntrod
ive c	vas ii
entat	ase v
orese	his c
al rej	iere t
tion	() wł
addi	ن ەن ئ
ls of	nel (6
letail	d pa
cal d	") an
ologi	Ψ.
pathe	(e.g.
l pue	gure
ical :	nts fi
Clin	Iesei
le 2	O rep
Tabj	ent II
tary	Pati
men	snce,
pple	ıvive
'n	10

	Diagnosis	Anaplastic Astrocytoma, IDH-wildtype, WHO Grade 3	Glioblastoma, WHO Grade 4	Glioblastoma, WHO Grade 4	Glioblastoma, WHO Grade 4	Anaplastic Oligodendroglioma. IDH-mutated, 1p19q codeleted, WHO Grade 3	Glioblastoma, WHO Grade 4	Glioblastoma, WHO Grade 4	Anaplastic Oligodendroglioma. IDH-mutated, 1p19q codeleted, WHO Grade 3	Glioblastoma, WHO Grade 4
	MGMT Promoter Methylation (Sequencing)	Negative	Negative	Positive	Negative	N/A	Negative	Positive	N/A	Negative
	p53 (IHC)	WT	WT	N/A	WT	WT	N/A	Mutant	WT	Mutant
	ATRX (IHC)	Retained	Retained	Retained	Retained	Retained	Retained	Retained	Retained	Retained
` )	IDH Method	Sequencing	Sequencing	IHC	IHC	IHC	IHC	IHC	IHC	IHC
-	IDH Status	WT	WT + BRAFV600 E Subclone	WT	WT	Mutant	WT	WT	Mutant	WT
)	Location	Right temporal	Right temporal	Left frontal	Left temporal	Left frontal	Left parietal	Right frontal	Left frontal	Right frontal
)	Sex	М	Female	Male	Male	Male	Male	Male	Male	Male
-	Age Range	51-55	66-70	66-70	56-60	51-55	56-60	61-65	56-60	66-70
	Primary vs Secondary	Primary	Primary	Primary	Primary	Recurrent	Primary	Primary	Primary	Primary
	Patient ID	F1C (Block 2E)	F2A (Block 2A)	F2B (Block 2A)	F2H, SF7-II (Block 2B)	F3B (Blocks 1A-1L)	SF7-I (Block 1A)	SF7-III (Block 2C)	SF7-IV (Block 2F)	SF7-V (Block 2A)